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http://dx.doi.org/10.1016/j.ccell.2015.01.002SUMMARYBlastemal histology in chemotherapy-treated pediatric Wilms tumors (nephroblastoma) is associated with
adverse prognosis. To uncover the underlying tumor biology and find therapeutic leads for this subgroup,
we analyzed 58 blastemal type Wilms tumors by exome and transcriptome sequencing and validated our
findings in a large replication cohort. Recurrent mutations included a hotspot mutation (Q177R) in the
homeo-domain of SIX1 and SIX2 in tumors with high proliferative potential (18.1% of blastemal cases);
mutations in the DROSHA/DGCR8 microprocessor genes (18.2% of blastemal cases); mutations in DICER1
and DIS3L2; and alterations in IGF2, MYCN, and TP53, the latter being strongly associated with dismal
outcome. DROSHA and DGCR8 mutations strongly altered miRNA expression patterns in tumors, which
was functionally validated in cell lines expressing mutant DROSHA.Significance
Very few driver genes have been identified thus far in Wilms tumors. Our identification of two prominent pathways—SIX1/2
and DROSHA/DGCR8—implicated in kidney development andmiRNA biogenesis, respectively, and both involved primarily
in blastemal type Wilms tumorigenesis, provides insight into the biology of these tumors. This is extended by our finding of
additionalmutations in other kidney developmental genes and a very high rate of IGF2 imprinting deregulation. Furthermore,
the strong negative impact of TP53mutations calls for thorough evaluation of such events. Altogether, our findings broaden
the spectrum of human cancer genes and may open avenues for stratification and therapeutic leads for Wilms tumors.
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INTRODUCTION
Wilms tumor affects 1 in 10,000 children. The Wilms tumor sup-
pressor gene WT1 was one of the first tumor suppressor genes
to be cloned (Call et al., 1990; Gessler et al., 1990), but the ge-
netic basis of these tumors remains heterogeneous and is still
poorly understood (Huff, 2011). Only about one-third of tumors
carry either a WT1 mutation—often combined with a CTNNB1
mutation—or an alteration affecting the WTX gene (Rivera
et al., 2007; Ruteshouser et al., 2008; Wegert et al., 2009).
TP53mutations appear to be restricted to rare anaplastic tumors
(Bardeesy et al., 1994), and other changes (e.g., alterations in
MYCN, FBXW7) are similarly uncommon (Williams et al., 2010),
leaving a significant fraction of cases without an identified
‘‘driver’’ genetic defect. Characteristic chromosomal aberrations
include deletions of chromosomes 1p and 16q as well as gain of
chromosome 1q (15%–30% each), but the critical genes in these
regions remain elusive (Grundy et al., 2005; Segers et al., 2013).
There is a strong epigenetic contribution to tumorigenesis since
more than one-third of cases exhibit loss of the maternal allele of
chromosome 11p15, or loss of imprinting (LOI) in the IGF2/H19
gene cluster (Scott et al., 2012). The limited prevalence and
prognostic value of currently known genetic alterations in Wilms
tumors indicate that significant drivers of initiation and progres-
sion remain to be discovered.
Patients are treated according to either Socie´te´ International
d’Oncologie Pe´diatrique (SIOP) (Europe and other countries) or
Children’s Oncology Group (COG) (North America) protocols
(Dome et al., 2013; Vujanic and Sandstedt, 2010). While COG
protocols are based on primary surgery followed by chemo-
therapy, SIOP patients usually receive preoperative chemo-
therapy, followed by surgery and adjusted postoperative
chemotherapy and radiotherapy. The difference in treatment
protocols leads to important differences in histological presenta-
tion and prognostic classification (Weirich et al., 2001). Wilms tu-
mors are histologically diverse, with variable contributions of
blastemal, stromal, and epithelial elements. While 35% of pri-
marily resected tumors are classified as blastemal predominant,
this fraction drops to 9.5% for cases evaluated following preop-
erative chemotherapy (Weirich et al., 2001). Blastemal contribu-
tion per se is not of prognostic significance in primarily resected
tumors. However, remaining viable blastema after preoperative
chemotherapy (SIOP protocol) is clearly associated with adverse
prognosis and reduced relapse-free survival (58.4% versus
86.7%) (Weirich et al., 2004). This is comparable to the adverse
outcome seen in conjunction with diffuse anaplasia and associ-
ated TP53 mutations (Lahoti et al., 1996). Therefore, character-
ization of the genetic basis of persistent blastema to identify
corresponding biomarkers or effective therapeutic leads is of
paramount clinical interest.
RESULTS
To define the genetic makeup of high-risk, blastemal type, post-
operative chemotherapy Wilms tumors, we performed exome
sequencing of 53 such tumors, supplemented with two relapse
samples, and corresponding normal controls. Three regressive
type tumors were included since they were followed by blas-
temal type relapses (WT002 and WT044) or generated a blas-Ctema-only xenograft (WT046) (Table S1). Exome analysis
(coverage 107–361 times) of these 58 cases was complemented
by low-coverage (1.2–3.9 times) whole-genome sequencing to
assess copy-number changes. Transcriptome analysis was car-
ried out by RNA sequencing (RNA-seq) (average of 4.3 3 107
reads) and on Affymetrix U133 Plus 2.0 arrays. Detailed
sequencing statistics are given in Table S2.
As expected for childhood tumors, the mean number of muta-
tions was low. On average, there were 14 (range of 0–75) somatic
single-nucleotide variations and small indels within protein cod-
ing exons per tumor with an average of 6 (0–15) non-synony-
mous mutations, including missense, stop loss, stop gain, and
splicing mutations. This is within the range seen for other pediat-
ric tumors, with an average of 0.14 mutations per Mb of coding
DNA (Figure S1) (Lawrence et al., 2013). 303 genes were found
to be mutated at least once, but only 18 genes were affected
twice or more (Figures 1A and 1B; for a complete listing see Ta-
ble S3). Seven of these genes (CRLF1, DCHS1, ABCA7, RYR2,
TTN,U2AF2, andNIPBL) were not analyzed further due to limited
evidence for functional relevance (see footnote in Table S3).
Stereotypic SIX1/2 Hotspot Mutations in Wilms Tumors
Themost prevalent somatic hotspotmutation was an A/G tran-
sition in exon 1 of the SIX1 transcription factor gene that leads to
a glutamine-to-arginine mutation at position 177 in the homeo-
domain in 6 of 58 cases (10%). In two instances, the wild-type
(WT) allele was lost, while the other four tumors carried heterozy-
gous mutations. Screening of a larger cohort of unselected
Wilms tumors by Sanger sequencing of genomic DNA (n = 188)
or allele-specific PCR (n = 529) identified 17 cases with the
Q177R mutation in SIX1, the majority being heterozygous (Ta-
ble 1; for details see Table S4). Intriguingly, two other tumors car-
ried the equivalent Q177Rmutation in SIX2, a highly homologous
gene known to act downstream of SIX1 in embryonic kidney
development. A survey of 405 additional cases by allele-specific
PCR identified another four SIX2 mutant tumors. In addition, we
found one truncating mutation in SALL1, a gene activated by SIX
proteins during metanephric development, indicating that the
entire signaling pathway may be critically involved in Wilms
tumorigenesis.
In 16 of 16 cases analyzed, the SIX1/2 mutations were so-
matic. Sequencing of cDNA showed that wild-type and mutant
alleles for SIX1 (n = 10) and SIX2 (n = 1) were expressed equally,
suggestive of a dominant effect. Besides blastemal tumors, the
mutations were also detected in regressive and necrotic tumors
that are thought to be derived from chemotherapy-sensitive
blastema, albeit at lower frequencies (Table 1). The much higher
incidence of SIX1/2 mutations in tumors with chemotherapy-
resistant blastema (14.1% [blastemal] versus 3.4% [regressive/
necrotic], and 0.7% [others] for SIX1) may indicate that these
mutations confer enhanced resistance to currently used drugs.
SIX1 and SIX2 have been proposed as blastemal markers in
Wilms tumors before, but no hint toward a function as a tumori-
genic driver has been identified to date (Sehic et al., 2012; Sen-
anayake et al., 2013). We detected strong nuclear staining for
SIX1 and SIX2 in blastemal cells, while epithelial and stromal
components remained almost completely negative. Importantly,
there was no obvious difference between blastemal tumors with
or without SIX1 or SIX2 mutations (Figure 2A).ancer Cell 27, 298–311, February 9, 2015 ª2015 Elsevier Inc. 299
Figure 1. Mutation Analysis of Wilms Tumors
(A) Presence of somatic or germline (G)mutations is indicated by black boxes. ForWTX, (1) specifies a hemizygous deletion in a female. The IGF2 imprinting status
is given as LOI, LOH, or regular monoallelic expression. In this case empty fields indicate missing or non-informative IGF2mRNA expression data and presence of
two DNA alleles. The genomic aberrations at each of the frequently altered regions and triploidy/tetraploidy are color coded. For chromothripsis patterns the
number of affected chromosomes is given.
(B) Recurrent somatic mutations in blastemal type Wilms tumors and selected single mutations affecting the same pathways. The location of coding and splice
site mutations as well as known protein domains are highlighted. Germline variants are shown in italics.
See also Figure S1 and Tables S1, S2, and S3.SIX1/2 Mutations Are Associated with a Proliferation
and Kidney Progenitor Cell Signature
To characterize the molecular signature of SIX1/2 mutations
in vivo, we performed gene expression analysis of 62 tumors,
including 32 with blastemal type histology, using Affymetrix ar-300 Cancer Cell 27, 298–311, February 9, 2015 ª2015 Elsevier Inc.rays. Unsupervised cluster analysis separated the tumors into
two prominent groups (Figure 2B). Group 1, enriched for blas-
temal type tumors (20/27) and characterized by upregulation of
cell-cycle genes and genes involved in kidney development,
contained all but two cases mutant for SIX1/2 (Figure 2B). Both
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CSIX1/2 mutants in group 2, however, did not express SIX1 or
SIX2. All tumors in group 1 expressed high levels of SIX1/2, while
expression levels in group 2 tumors were generally lower (Fig-
ures 2C and 2D). Interestingly, the eight SIX1/2 mutants in
group 1 all clustered together. A direct comparison of these
SIX1/2 mutants with the other 19 tumors in group 1 (all wild-
type for SIX1/2) showed that many cell-cycle genes, already up-
regulated in group 1 tumors, are even further upregulated in
SIX1/2 mutant tumors (Figures 2E–2H). Group 1 tumors are
further characterized by a concerted and strong expression of
other SIX and SALL family members and the SIX cofactor gene
EYA1, together with other kidney developmental genes (e.g.,
CITED1, NCAM1, GDNF, REST, and MYCN), indicative of a
kidney progenitor cell state. Group 2 tumors are far more hetero-
geneous, with a stronger expression of genes involved in differ-
entiation and maturation (transport, adhesion, extracellular
matrix secretion) or inflammatory/immune responses and a
less prominent association with specific mutations (Figure 2B).
SIX1 Mutations Alter DNA Binding
The known crystal structure of the SIX1 protein suggests that the
Q177R mutation affects its DNA binding properties since super-
position of the structurally highly conserved homeodomain fold
onto the ternary complex formed between HoxB1-Pbx1 and
DNA (Piper et al., 1999) places this residue in the major groove
of the bound DNA (Figure 3A) (Patrick et al., 2013). Activation
of the promoters of the well-established SIX1/2 targets SIX2
and SALL1 is not altered in luciferase assays, however, and
wild-type and mutant SIX1 locates to the nucleus (Figures 2A,
3B, and S2).
To search for in vivo differences in DNA binding, we performed
chromatin immunoprecipitation sequencing (ChIP-seq) using an
SIX1 antibody. Two tumors with high levels of SIX1 WT mRNA
(WT010/WT088) and one tumor with comparable expression of
a homozygous SIX1-Q177R mutation (WT047) were used;
60,000 peaks were identified in each case. Binding motif anal-
ysis extracted a consensus SIX1 motif in the two cases with WT
SIX1 (correlation of 0.98 and 0.95), while the mutant tumor only
yielded a more divergent motif (correlation of 0.86) (Figure 3C;
Table S5). Intriguingly, peaks with significantly reduced binding
in the mutant tumor, where WT SIX1 is presumed to bind more
strongly, still allowed retrieval of an SIX1 consensus site (corre-
lation of 0.93). However, peaks with increased binding in the
mutant tumor generated an even more divergent motif (correla-
tion of 0.69), pointing to a distinct, SIX1-Q177R preferred site.
Key differences are the loss of a requirement for TG at positions
7 and 8 and the gain of a C requirement at position 10 in the bind-
ing motif.
These data suggest that the Q177R mutation shifts DNA
binding specificity, which may induce subtle changes in the
gene regulatory capacity of SIX1, in line with the gene expres-
sion analysis in group 1 tumors described above. An example is
the upregulation of TGFA in SIX1 mutant tumors and the
enhanced binding of SIX1-Q177R immediately upstream of
the transcription start site and in two intronic regions, harboring
sequences corresponding to the mutant-specific motif (Figures
3D and 3E). Full elucidation of the functional impact of SIX1
mutations will require analysis of a larger set of tumors to derive
final conclusions.ancer Cell 27, 298–311, February 9, 2015 ª2015 Elsevier Inc. 301
Figure 2. Expression Analysis in SIX Mutant Wilms Tumors
(A) Examples of immunohistochemical staining with SIX1 and SIX2 antisera in SIX1WT and mutant (Q177R) tumors. Note that blastemal nuclei show prominent
staining whereas the epithelial component (tubulus) has no nuclear expression, only a weak cytoplasmic positivity. Scale bar, 50 mm.
(B) Gene expression profiling of 62 Wilms tumors. 35 cases are from the exome analysis cohort, supplemented with tumors representing other histological
subtypes. Mutations and blastemal subtype are indicated by colored boxes. Two main groups are identified upon K-means clustering that differ in expression of
three gene classes as categorized by gene ontology (GO) term analysis.
(C–H) Expression profiles for SIX1 (C), SIX2 (D), AURKB (E), BUB1B (F), CITED (G), and MYCN (H) shown as boxplots with arbitrary expression units. Boxes
represent the middle 50% of data (circles) with a central line at the median. Whiskers represent extremes (up to 1.5-fold box size).
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Figure 3. Functional Characterization of SIX1 Mutations
(A) Illustration of the Q177 containing helix of the SIX1 homeodomain inserted into the major groove of DNA. The high-resolution SIX1-EYA2 structure (PDB entry
4EGC) was superposed onto the coordinates of the HoxB1 crystal structure within its ternary complex with Pbx1 and DNA (PDB entry 1B72).
(B) Activation of themouseSix2 and the humanSALL1 promoters by expression of SIX1 or SIX1-Q177R in themurinemesonephric cell lineM15. Values represent
mean ± SD of luciferase expression levels relative to empty vector control (set to 1). Measurements were done in triplicates.
(C) SIX1 binding motifs identified in SIX1WT (T1, T2) andmutant (T3) tumors by ChIP-seq. Note that peaks reduced or increased in the SIX1mutant tumor identify
different binding motifs.
(D) Expression of TGFA in indicated group of tumors. Gray bar indicates mean expression value (arbitrary units).
(E) ChIP-seq profile around the TGFA start site. Three prominent peaks in tumor T3 harbor the variant SIX1 binding motif (arrows).
See also Table S5.
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Figure 4. miRNA Processing Mutations and Their Functional Consequences
(A) Position of the DROSHA RNase IIIb domain mutations. The E1147K, Q1187K, and E1222Kmutations affect the active site of the RNase IIIb domain and its two
metal binding sites A and B, while I1225M disturbs an adjacent hydrophobic core. D1204Y involves a possible contact to the dsRNA substrate.
(legend continued on next page)
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Microprocessor Gene Mutations in Wilms Tumors
The second most prevalent set of somatic mutations affected
DROSHA and DGCR8, encoding the main components of the
miRNA microprocessor complex (Figure 1). This complex pro-
cesses primary miRNAs in the nucleus to form pre-miRNAs,
which in turn are substrates to subsequent processing by
DICER1 in the cytosol. Four of the fiveDROSHAmutations affect
one of three key metal binding amino acids of the RNase IIIb
domain that are thought to be essential for catalysis (Gan
et al., 2006) (Figure 4A). In each case glutamic acid is replaced
by lysine at amino acid 1147 (three times) or 1222 (once). The fifth
mutation D973H is located in the catalytic center of the RNase
IIIa domain (Gan et al., 2006) (Figure 4B).
Screening of another 363 cases by allele-specific PCR identi-
fied 13 additional tumors with the DROSHA E1147K mutation
(Tables 1 and S4). Direct sequencing of the DROSHA cDNA for
the RNase IIIa and IIIb domains in an independent set of 100
Wilms tumors detected seven additional somatic mutations
(S990R, two times E993K, E1147K, Q1186K, D1204Y, and
I1225M). TheQ1186 and I1225 residues are again part of the cat-
alytic center, while S990, E993, and D1204 are located outside.
From a superposition of homology models of both DROSHA
RNAase III domains with the high-resolution crystal structure of
Aquifex aeolicus RNase III complexed with a double-stranded
RNA (dsRNA) substrate (Gan et al., 2008), we predict that the
D1204Y and E993K mutations are oriented toward and likely
contact the dsRNA substrate (Figures 4A and 4B). Of note, these
mutations were always heterozygous in tumor DNA and cDNA
without evidence for additional alterations on the second allele.
For eight tumors, multiple biopsies (up to six) were available,
and all exhibited heterozygous mutations. This clearly is sugges-
tive of a dominant effect.
The changes in the DROSHA partner protein DGCR8 were
even more striking. Four tumors in the exome sequencing cohort
showed hotspot mutations leading to a single amino acid alter-
ation with charge reversal (E518K) in the RNA binding domain
(Figure 4C). In one tumor, a homozygous single-nucleotide inser-
tion resulted in a frameshift with early protein truncation after
amino acid 81, while a sixth tumor had a heterozygous E213X
nonsense mutation. Allele-specific PCR for the E518K alteration
followed by sequencing on 719 additional cases revealed the
presence of the identical mutation in 20 additional tumors, lead-
ing to a cumulative incidence of 3.2% (Tables 1 and S4).
In contrast to the heterozygous alterations in DROSHA, muta-
tions in DGCR8 were homozygous in many cases (Table S4).
However, several tumors with missense mutations that retained
awild-type allele expressed only themutant allele, indicating that(B) The D973H mutation affects the active site of the DROSHA RNase IIIa doma
distant position involving a putative contact to the dsRNA substrate.
(C) The DGCR8 E518Kmutation in a presumptive protein dsRNA complexmodele
complex. Affected residues are rendered in magenta.
(D) miRNA expression profiling separates tumors with mutations in the micropro
clustering was done with the 50 most discriminative small RNA features. miRNA p
probes had adj. p values of 1.1 3 106 or less.
(E) Changes of miRNA profiles in HEK293T cells upon inducible expression of
hybridized onto Agilent miRNA arrays. RNAs with >50% presence calls by the fe
highlight clusters of small RNAs that either feature or lack characteristics of cano
See also Table S6.
Cthe mutation must act recessive. DGCR8 is located on chromo-
some 22q11 and the known adverse effect of loss of heterozy-
gosity (LOH) of 22q (Klamt et al., 1998) may in part be due to
the involvement of DGCR8. Indeed, of the six DGCR8 mutant
cases from the exome sequencing cohort, three had deletions
and two had LOH of chromosome 22q.
Surprisingly, there was a striking sex bias inDGCR8mutations
since 23 of 26 cases (88%; p = 0.003, c2 test) arose in girls, while
there was a similar distribution of male and female patients in the
entire cohort (343 versus 430) and for all other recurrent muta-
tions. There is no evidence for sex-specific expression or
imprinting in the corresponding genomic region and RNA
sequencing data from non-mutant cases of our cohort did not
provide evidence for monoallelic expression of other informative
DGCR8 SNPs that would explain this bias.
The known crystal structure of DGCR8 suggests that the
amino acid change seen in Wilms tumors may disrupt the strong
interaction of three neighboring amino acids via a hydrogen-
bonding network (not shown). Although there is no co-structure
available with bound RNA, superposition onto the ADAR2 dou-
ble-stranded RNA binding motif (dsRBM)-RNA complex (Stefl
et al., 2010) suggests that the mutated residue may be involved
in readout of the minor groove or in contacts to the ribose/phos-
phate backbone (Figure 4C). This could have severe conse-
quences for target selectivity and activity of the microprocessor
complex.
There was a significant overlap of DROSHA and SIX1 muta-
tions with 17 DROSHA, 17 SIX1, and 6 double mutant tumors
(p < 106). On the other hand, a combined mutation of SIX1
and DGCR8 was detected just once, suggesting that only the
link between SIX1 and DROSHA may be functionally significant
and synergistic.
Germline Mutations
Wherever DNA from blood leukocytes or adjacent normal kidney
was available, we also checked for possible germline mutations.
There were eight cases affecting DROSHA (two times R279C),
DGCR8 (two times K588R), DICER1 (G1886R), and DIS3L2
(Y137C, P514X, and Q827X), and some are predicted to be dele-
terious (Table S4). Although all mutations are truncating or affect
conserved residues, only the DIS3L2 P514X mutation became
homozygous in the tumor, supportive of functional importance.
These constitutional heterozygousmutations appear compatible
with normal development, but may still pose an increased tumor
risk as proposed by Foulkes et al. (2014) in the case of DICER1.
Some of these mutations are also present at low frequency in
reference exome sequences (Exome Aggregation Consortiumin (within the box) and its two metal binding sites, while E993K is located at a
d according to the known DGCR8 structure and a related ADAR2-dsRMB-RNA
cessor genes DROSHA and DGCR8 from non-mutated controls. Hierarchical
rocessing mutations are listed with germline changes marked by asterisks. All
wild-type or E1147K mutant DROSHA. Duplicates of biological replicas were
ature extraction software are shown in black; all others are in gray. Triangles
nical miRNAs according to miRBase.
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Figure 5. Examples of Chromothripsis Patterns in Wilms Tumors
Tumor and chromosome numbers are given above each graph that represents one affected chromosome each. Copy-number changes appear as deviation from
the expected two copy values, calculated from the genome-wide median.
See also Figure S3 and Table S7.[ExAC]; http://exac.broadinstitute.org/), but none of the more
frequent SIX1/2 or microprocessor mutations has been found
there.
Microprocessor Mutations Alter miRNA Expression
Patterns
DROSHA/DGCR8mutations did not have a strong effect on gene
expression levels as the mutant tumors did not cluster together
like the SIX1/2 mutants did (Figure 2B). We also characterized
the effects ofDROSHA/DGCR8mutations onmiRNA processing
and compared miRNA profiles in 30 DROSHA/DGCR8/DICER1/
DIS3L2 mutant with 31 non-mutant tumors. There was a clear
distinction with DROSHA/DGCR8 mutant tumors forming a
separate group upon unsupervised hierarchical clustering based
on the 50 most discriminative miRNAs (Figure 4D). Tumors with
DROSHA and DGCR8 mutations were intermingled upon clus-
tering, suggesting that these mutations have very similar effects.
Only two cases with common mutations had miRNA profiles
indistinguishable from tumors devoid of microprocessor muta-
tions. In total, 320 (27%) of small RNAs tested exhibited signifi-
cant expression differences between wild-type and mutant
tumors (adjusted [adj.] p < 0.05), indicative of broad alterations
in miRNA processing (Table S6). Notably, the DGCR8 stop mu-
tations as well as the DICER1, DIS3L2, and N-terminal DROSHA
mutations had limited or no effect on miRNA patterns, indicating
that they may only affect a smaller subset of miRNAs.
To functionally assess DROSHAmutations, we generated hu-
man embryonic kidney 293T (HEK293T) cells with inducible over-
expression of wild-type ormutantDROSHA. Expression levels of
endogenous and transgene DROSHA mRNA were similar by
qRT-PCR, mimicking the heterozygous mutations in Wilms tu-
mors. Induction of WT DROSHA did not alter the miRNA pattern
as tested on Agilent Technologiesmicroarrays. Expression of the
DROSHA E1147K mutant, however, led to a downregulation of
many of the expressed small RNAs. All 145 miRNAs with signifi-
cant regulation (adj. p < 0.05) showed a reduced expression306 Cancer Cell 27, 298–311, February 9, 2015 ª2015 Elsevier Inc.(average fold-change of 1.7 times) upon DROSHA-E1147K in-
duction (Figures 4E and 4F; Table S6). Strikingly, these RNAs
are mostly classified as high-confidence miRNAs according to
miRBase (Kozomara and Griffiths-Jones, 2014), while almost
no short RNA with unaltered expression can be classified as ca-
nonical miRNA. This clearly is different from DICER1 syndrome
and points to a dominant and global miRNA processing defect
of the DROSHAmutant in heterozygous tumor cells.
TP53Mutations Are Associated with Aneuploidy,
Chromothripsis, and Poor Outcome
The homozygous TP53 mutations reported here affect known
hotspots (R175, R248, and R342) or lead to a premature stop
in six tumors, while a seventh tumor (WT030) has a homozy-
gous deletion (Figures 1A and 1B; Table S3). Histology was
classified as blastemal type, but some cases exhibited addi-
tional focal or even diffuse anaplasia. This is in line with the pre-
vious link of TP53 mutations to anaplastic Wilms tumor and the
presence of a histologic continuum including nuclear unrest
(Bardeesy et al., 1994). These mutations seem to induce
genomic instability since four of the tumors were tetraploid/
aneuploid and all seven featured a chromothripsis pattern (Fig-
ures 1A, 5, and S3; Table S7). Of note, there was only a single
case without TP53 alteration that featured a chromothripsis
pattern, further strengthening a causal link between germline
or early somatic TP53 mutation and chromothripsis as pro-
posed for medulloblastoma and several other entities (Rausch
et al., 2012).
One of the TP53 mutations (R342P; WT015) affecting the
tetramerization domain was also present in the germline, indic-
ative of Li-Fraumeni syndrome. Most importantly, all seven pa-
tients with TP53 mutations died. There were only two additional
fatal cases in our series without a TP53 alteration, highlighting
the massive negative impact of such mutations. Even with an
additional 11 cases in our cohort showing active disease (1)
or short follow-up of less than 2 years (10), it appears that
Figure 6. Chromosomal Copy-Number Changes and Allele Loss in Wilms Tumors
Copy-number changes were assessed on low-coverage whole-genome sequences, quantified using 10-kb bins and then mapped to cytobands. The red line
denotes abundance of allele loss (LOH) based on BAF. See also Table S7.TP53 mutations are the most relevant aberration mediating
poor outcome.
Mutations Affecting MYCN in Wilms Tumors
The MYCN gene was affected in two ways: one tumor showed
point mutations in both alleles of the MYCN gene (WT052:
P44L, P44T) and the P44L mutation was also found in tumors
WT031 and WT038—in the latter only in a fraction of cells (Fig-
ure 1A). Furthermore, low copy amplification ofMYCN including
only one to seven flanking genes was seen in five cases
(including WT052), based on whole-genome and exome ana-
lyses, yielding a 14% frequency ofMYCN alterations in blastemal
type tumors. Analysis of another 200 Wilms tumors by multiplex
ligation-dependent probe amplification (MLPA) yielded a similar
incidence of 16.5% low-copy number MYCN gain with no
apparent preference for certain histological subtypes. Allele-
specific PCR revealed P44L mutations in three regressive and
one stromal type tumors, indicating that these are recurrent
events (Tables 1 and S4), with an overall frequency ofMYCN al-
terations of 18.5%. There were also tumors with a missense mu-
tation (subclonal in WT026) or focal heterozygous deletions of
FBXW7 (four times), which is known to destabilize MYCN (Fig-
ure 1A). Furthermore, one tumor had a somatic R60Q mutation
in MAX, which encodes a MYC heterodimerization partner that
is the most frequent change reported in the COSMIC database
(https://www.sanger.ac.uk). The mutation strongly alters the
main contact to the phosphate backbone of DNA and may shift
the balance toward pro-tumorigenic MYCN/MIZ1 complexes.
The effect of MYCN mutation status on expression levels could
not be quantitated due to insufficient numbers of cases in the
cohort analyzed. In general, expression of MYCN correlated
with high SIX1/2 expression and a proliferation signature
(Figure 2H).
Additional Mutations Are Found at Lower Frequency
WTX alterations are less frequent in our cohort compared to un-
selected Wilms tumors (Wegert et al., 2009), with complete de-
letions in two males and hemizygous losses in three females
(Figure 1A). In two female cases RNA was available, with one
exhibiting very low WTX expression (<10% average), sugges-
tive of a functional deletion. The well-established Wilms tumor
genes CTNNB1 and WT1 were mutated twice and once,
respectively. This low incidence is certainly due to their prefer-Cential association with a different, i.e., stromal subtype. There
were three cases with germline mutations in HACE1, a gene
implicated in Wilms tumor formation, but it is unclear whether
the alterations seen in prior studies instead affect the neigh-
boring LIN28B locus that is clearly involved in Wilms tumor for-
mation (Slade et al., 2010; Urbach et al., 2014; Viswanathan
et al., 2009).
Other mutations detected twice within the screening cohort
(CHD4, GLI3, REST, and RERE) point toward an impaired differ-
entiation of kidney precursor cells since these genes are known
to be expressed conspicuously during kidney development or
maintain key roles in precursor cell differentiation.
Imprinting Defects and Chromosomal Imbalances Are
Frequent in Blastemal Type Wilms Tumors
There is a very high incidence of chromosome 11p15 alterations,
predicted to affect IGF2 expression in our series of blastemal
type tumors. The IGF2 gene is active on the paternal allele
only, due to genomic imprinting. LOI or LOH involving 11p15
with almost invariant duplication of the paternal allele lead to
two active gene copies. Only 8 of 42 informative cases had reg-
ularmonoallelic expression, while 15 showed biallelic expression
(LOI) and another 19 exhibited copy-number neutral LOH with
likely two active paternal IGF2 alleles (Figure 1A). Thus, 81% of
cases show evidence of imprinting defects and allele loss with
concomitant increased expression of IGF2 (average increase:
2.4 times, LOI; 2.7 times, LOH). The adjacent H19 gene shows
monoallelic expression in all tumors, indicative of an uncoupling
of H19 and IGF2 imprinting, which has been reported previously
(Bjornsson et al., 2007). This clearly demonstrates that the IGF2
status is of particular importance for blastemal type Wilms
tumors.
The recurrent gene mutations reported here affect 74% of
tumor samples and substantially expand the known repertoire
of driver genes in Wilms tumorigenesis. In addition, there are
further recurrent genomic copy-number alterations (CNAs) and
allelic losses that affect multiple chromosomes or segments
thereof in >75% of tumors (Figures 1A and 6; Table S7). The
most frequent change is gain of chromosome 1q, often in
conjunction with deletion of 16q, suggestive of an unbalanced
t(1q:16q) translocation or isochromosome 1q described cytoge-
netically previously (Segers et al., 2013). Deletions of chromo-
some 1p and 22q (location of DGCR8) are also frequent as areancer Cell 27, 298–311, February 9, 2015 ª2015 Elsevier Inc. 307
gains of chromosomes 6, 7q, 12, or 18 (Table S7). These data are
in general agreement with previous findings (Natrajan et al.,
2006), but do not identify novel blastema-specific alterations.
DISCUSSION
Whole-genome analyses have provided insight into a number of
tumor entities and have helped to expand the known repertoire
of oncogenic driver mutations in human tumors (Lawrence
et al., 2013). In pediatric Wilms tumors, only three genes (WT1,
CTNNB1, and WTX) have been found mutated at R10% fre-
quencies to date. Inmany cases, a clear-cut genetic defect is still
missing. We now identify several additional genes that are candi-
date oncogenic drivers in Wilms tumors, and most of these
genes are apparently specific for this tumor entity, suggesting
a unique pathway of tumor formation.
The most striking additions to the repertoire of Wilms tumor
genes are SIX1, SIX2, and the microprocessor components
DROSHA and DGCR8. SIX1, SIX2, and SALL1 are key transcrip-
tion factors formouse kidney development andmay characterize
Wilms tumor initiating cells (Brodbeck and Englert, 2004; Pode-
Shakked et al., 2013). They are essential for signaling and expan-
sion of the blastemal cell compartment that is induced by the
ureteric bud to proliferate and to differentiate into nephrons.
Loss of any of these genes leads to kidney agenesis or reduced
size, most likely due to reduced proliferation and premature dif-
ferentiation of blastemal cells (Yu et al., 2004). In addition, Six1
and Six2 are part of a gene set that allows reprogramming of
adult kidney tubule cells into nephron progenitors (Hendry
et al., 2013). These observations imply that hyperactivation of
this pathway may lead to excessive proliferation of blastemal
cells and thus blastemal type Wilms tumors. Indeed, high
expression of SIX1 and SIX2 has been reported in Wilms tumors
(Sehic et al., 2012; Senanayake et al., 2013), but it remained un-
clear whether this represented an oncogenic driver or only re-
flected the blastemal differentiation state of tumor cells.
The somatic SIX1 and SIX2mutations described here have not
been reported before. However, a parallel study by Walz et al.
(2015 in this issue of Cancer Cell) detected such mutations at a
7% frequency in a large cohort of favorable histology Wilms tu-
mors, also with a preference for blastemal histology, thus vali-
dating our findings. The stereotypic location affecting a single
amino acid residue that appears to be involved in DNA binding
clearly points to a regulatory role. The heterozygous mutations
and equal expression of both alleles in most cases suggests
that novel functions are gained in a dominant manner. While
mutant SIX1 can still activate classic target promoters, our
ChIP-seq experiments uncovered a shift in DNA binding prefer-
ence that is paralleled by discrete changes in expression profiles
in mutant tumor samples. Thus, SIX1/2 mutations may drive
oncogenesis through subtle quantitative effects on a prolifera-
tion mRNA signature of embryonic precursor cells.
Germlinemutations in SIX1were previously described in bran-
chiootorenal (BOR) syndrome, but the SIX1 mutations found in
those patients are different from the somatic mutations
described here and they only affect regions N terminal to Q177
(Ruf et al., 2004). Although BOR syndrome can be accompanied
by renal developmental defects, there is no report of tumor pre-
disposition, suggesting that the mechanisms are different. The308 Cancer Cell 27, 298–311, February 9, 2015 ª2015 Elsevier Inc.SALL1 mutation detected in one of our cases is similar to trun-
cating mutations seen in Townes-Brocks syndrome, where
rare kidney defects but no Wilms tumors were reported previ-
ously (Kohlhase et al., 1998).
The combined evidence from human tumor data and mouse
knockout models thus supports a critical role for the SIX1/2
pathway not only in the control of kidney development but also
as an oncogenic driver in malignant transformation that may be
testable in animal models.
Processing defects ofmiRNAs have been implicated in several
human tumors—including Wilms tumor—through DICER1muta-
tions affecting the RNase IIIb domain (Wu et al., 2013). This leads
to preferential processing of 3p versus 5p miRNAs (Anglesio
et al., 2013). Although most of the DROSHA mutations in Wilms
tumors map to the RNase IIIb domain, there is no evidence for
such an effect. Our data rather suggest that the mutations lead
to a global reduction inmanymiRNAs irrespective of their deriva-
tion from the 50- or 30-strand. Thus, these microprocessor muta-
tions must act different from the ones observed in DICER1 syn-
drome, which may be explained by the fact that incompletely
processed pre-miRNAs will fail to be exported from the nucleus.
For DGCR8 there are no comparable alterations in the literature.
While the highly specific E518K mutations in DGCR8 point to a
more focused processing defect, the similarity of miRNA profiles
with DROSHA mutant tumors would argue instead for a global
processing defect.
Mutations of the let-7miRNA processing factors DIS3L2 (Perl-
man syndrome, predisposing toWilms tumor) (Astuti et al., 2012)
and LIN28B (tumor-specific translocations) (Viswanathan et al.,
2009) already point to a critical role for miRNA processing in
Wilms tumor. Furthermore, transgenic overexpression of Lin28
in kidney precursors resulted in a mouse model of Wilms tumor
formation (Urbach et al., 2014). The apparent limitation to let-7
miRNAs reflects a clear difference to the microprocessor muta-
tions with much broader specificity, which is also supported by
the more regular miRNA patterns observed in our DICER1 and
DIS3L2 mutant cases.
Similar mutations of DROSHA and DGCR8, as well as a small
number of mutations in XPO5 and TARBP2 of unclear signifi-
cance, have recently been reported together with altered miRNA
patterns in mutant tumors (Rakheja et al., 2014; Torrezan et al.,
2014; Walz et al., 2015). The large-scale study by Walz et al.
(2015) furthermore identified a strong preference for blastemal
histology, a high frequency of perilobar nephrogenic rests and
imprinting defects, and a strong bias toward females in the
case of DGCR8mutations. These studies likewise found hetero-
zygous, dominant-negative DROSHA mutations, but homozy-
gous DGCR8 inactivation. Taken together with our results and
the fact that Dgcr8/ embryonic stem cells (ESCs) are unable
to downregulate the self-renewal program and to proceed into
differentiation (Melton et al., 2010), microprocessor genes
appear to represent excellent candidates for drivers of blastemal
type Wilms tumors. These mutations may facilitate evasion from
the final round of precursor cell differentiation in the developing
kidney, leading to continuous proliferation of blastemal precur-
sor cells.
Although low-level MYCN amplification has been found in
Wilms tumors before, the specific mutations of codon 44 within
the Aurora A kinase interaction domain that regulates MYCN
stability has not. 14MYCN alterations at codon 44 have been re-
ported in the COSMIC database (endometrium, neural, intestine,
and pancreas; https://www.sanger.ac.uk). Four cases of high-
risk neuroblastoma showing this mutation have been published
combined with evidence for a functional relevance from
sequence homology with MYC and computational analyses
(Pugh et al., 2013). Furthermore, MYCN amplification and over-
expression have been associated with adverse prognosis in
Wilms tumors (Williams et al., 2010; Zirn et al., 2006). This under-
scores the importance of the observed mutations and indicates
that MYCN can be affected on multiple levels, especially since
we detected further mutations of the FXBW7 and MAX genes,
which may also support oncogenic MYCN function.
An important outcome of the current profiling is that TP53mu-
tations are a key contributor to lethality in blastemal type Wilms
tumor. Such mutations have been described as being almost
pathognomonic of anaplastic Wilms tumors. In our series, tu-
mors with such mutations had anaplastic features to a varying
extent and were invariably associated with chromothripsis and
poor outcome. This indicates that screening for such alterations
may be advisable in routine diagnosis, especially if there is any
hint of anaplasia.
The overall low prevalence of gene mutations in blastemal
type Wilms tumors clearly suggests that part of the molecular
basis is yet to be uncovered, especially since most regions
with recurrent chromosomal gains and losses lack clear candi-
date target genes. The very high incidence of IGF2 alterations
(LOI and LOH) with elevated mRNA expression in 81% of cases
highlights that the known involvement of this gene in Wilms tu-
mors seems to be even more important in blastemal type tu-
mors, where IGF2 may serve as a growth and survival factor
for blastemal cells.
Our identification of two prominent pathways—SIX1/2 and
DROSHA/DGCR8—involved preferentially in blastemal type tu-
mors provides insight into the biology of these tumors. Notably,
these genes have not been found as mutated drivers in other tu-
mor types before, suggesting that blastemal type Wilms tumors
represent a very special molecular entity, even among pediatric
cancer. Several of the genes mutated at lower frequency are
involved in the control of progenitor cell self-renewal and the
exit from proliferative compartments into terminal differentiation.
This clearly suggests that in blastemal type Wilms tumors these
progenitor cells fail to exit the physiologic embryonic growth
compartment, which should make tumors amenable to differen-
tiation-inducing therapies. A better definition of high-risk cases
based on these candidate genes may in addition allow for further
reduction in treatment intensity for subtypes that have an excel-
lent prognosis with current regimens.
EXPERIMENTAL PROCEDURES
See Supplemental Experimental Procedures for details.
Samples
Wilms tumor and control tissues were obtained from the German SIOP93-01/
GPOH and SIOP2001/GPOH studies and collaborating European centers. All
subjects (or their parents) provided written consent for tumor banking and
future research use according to national regulations: Ethikkommission der
A¨rztekammer des Saarlandes, 136/01 (Germany); Trent MREC/98/04/023/
BD2 (the Netherlands); Ethics Committee Kanton Zurich (Switzerland) withinCan international clinical study (Nr 6/02); Trent MREC/01/4/086 (UK); Medical
Research Ethics Committee of Our Lady’s Children’s Hospital, Crumlin, Dublin
12 (Ireland); and Regional Andalousian Ethics Committee, Seville (Spain).
Sample names were coded at the sites of collection and further pseudony-
mized for central processing.DNA Sequence Data Generation and Processing
Whole-genome sequencing libraries were prepared using Illumina v.2 proto-
cols. Exome capturing was carried out with Agilent SureSelect Human All
Exon v.4 50 Mb in-solution capture reagents. Paired-end DNA sequencing
reads (Illumina HiSeq 2000) were mapped to the 1,000 genomes phase 2 refer-
ence assembly (hs37d5) using BWA and alignments were merged using
SAMtools (Li et al., 2009). PCR duplicates were marked using Picards tools
(http://broadinstitute.github.io/picard).DNA Variant Detection
Single-nucleotide variants (SNVs) and small insertions/deletions (indels) were
identified using an in-house analysis pipeline based on SAMtools, mpileup,
and bcftools. CNAs were identified by use of low-coverage whole-genome
sequencing reads of tumors and comparison of tumor and control exome
pairs. LOH events were identified from B-allele frequency (BAF) plots gener-
ated from the SNV call using custom Perl scripts.RNA-Seq Analysis
RNA-seq libraries were prepared using the Illumina TruSeq RNA Sample Prep-
aration Kit v.2 and sequenced (Illumina HiSeq 2000) using 101-bp paired-end
reads. RNA-seq reads were trimmed to remove low-quality bases and adaptor
contamination using TrimGalore andmapped to the hs37d5 genome assembly
with the GENCODE v.13 annotation as a transcript guide using Tophat.
Expression values were reported as fragments per kilobase of exon per million
fragmentsmapped (FPKM) as calculated byCuffDiff. Allele specific expression
was calculated as an average of all DNA SNV positions with at least ten reads
and minor allele frequency of 15%.Verification of SNVs and Indels
For recurrently mutated genes, SNVs were verified by Sanger sequencing of
genomic DNA. Expression of mutant alleles was tested on corresponding
cDNA fragments. To screen larger tumor sets for distinct mutations, allele-spe-
cific PCR was performed with primers designed using WebSNAPER (http://
pga.mgh.harvard.edu/cgi-bin/snap3/websnaper3.cgi), and variants were veri-
fied by direct sequencing.Microarray Analysis
Wilms tumor RNA was analyzed on Affymetrix GeneChip Human Genome
U133 Plus 2.0 arrays. The MAS5.0 algorithm was used for normalization.
Data were analyzed using R2 (R2.amc.nl) or TM4 software (Saeed et al., 2003).
miRNA expression profiles were obtained using the HumanmiRNAMicroar-
ray Kit (release 16.0) and Feature Extraction Software (Agilent). Data were
analyzed using the R/bioconductor package (http://www.bioconductor.org).
Differences in miRNA expression were identified using the limma package
(Smyth, 2005).ChIP-Seq Data Generation and Analysis
Chromatin was immunoprecipitated from tumors with comparable expression
of wild-type or mutant SIX1 (anti-SIX1, HPA001893, Sigma) by Active Motif.
Sequencing was performed on the HiSeq 2500 platform using the Rapid
Run settings. 100-bp paired-end reads were mapped to the 1,000 genomes
phase 2 reference assembly (hs37d5) using BWA-MEM, and alignments
were merged using SAMtools.Mutation Modeling
Molecular images were generated with the program PYMOL (Schro¨dinger).
For details on crystal structures used, see Supplemental Experimental
Procedures.ancer Cell 27, 298–311, February 9, 2015 ª2015 Elsevier Inc. 309
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